phase I trial

A phase I trial is a drug's first cautious meeting with the human body. After years of work in test tubes and animals, this is the moment researchers find out whether a person can take the drug at all, and at what dose, before anyone asks whether it cures anything. The guiding question is not 'does it work?' but 'is it safe enough to keep going, and what does the body do with it?'

Such trials are small, often only a few dozen people, and frequently use healthy volunteers because the goal is to see the drug's effects without the confusion of disease. Researchers usually start at a very low dose and raise it step by step in successive small groups, watching closely for adverse reactions. At the same time they take frequent blood samples to map the pharmacokinetics: how fast the drug is absorbed, how high its concentration climbs, and how quickly it is cleared.

From this, investigators learn the maximum tolerated dose, the kinds of side effects to expect, and a sensible dose range to carry into the next phase. For drugs that are themselves toxic, such as cancer chemotherapy, healthy volunteers cannot ethically be exposed, so phase I is done in patients who have the disease and few other options.

Because the numbers are tiny and the people are usually atypically healthy, a phase I trial proves very little about whether the drug treats illness. A clean safety profile here is necessary but nowhere near sufficient; many drugs that sail through phase I later fail to show benefit, and some rare or delayed harms only surface much later.